N‐substituted Piperazinopyridylsteroid Derivatives as Abiraterone Analogues Inhibit Growth and Induce Pro‐apoptosis in Human Hormone‐independent Prostate Cancer Cell Lines. (16th October 2013)
- Record Type:
- Journal Article
- Title:
- N‐substituted Piperazinopyridylsteroid Derivatives as Abiraterone Analogues Inhibit Growth and Induce Pro‐apoptosis in Human Hormone‐independent Prostate Cancer Cell Lines. (16th October 2013)
- Main Title:
- N‐substituted Piperazinopyridylsteroid Derivatives as Abiraterone Analogues Inhibit Growth and Induce Pro‐apoptosis in Human Hormone‐independent Prostate Cancer Cell Lines
- Authors:
- Brossard, Dominique
Zhang, Ying
Haider, Shozeb M.
Sgobba, Miriam
Khalid, Mohamed
Legay, Rémi
Duterque‐Coquillaud, Martine
Galera, Philippe
Rault, Sylvain
Dallemagne, Patrick
Moslemi, Safa
El, Laïla - Abstract:
- <abstract abstract-type="main" id="cbdd12195-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Nine new 17‐(piperazin‐1‐yl)pyridin‐5‐yl)steroids as abiraterone analogues were synthesized. Compounds <bold>5d</bold> and <bold>5g</bold> showed selective activities against 17α‐hydroxylase/C17, 20‐lyase (CYP17A1) and aromatase (CYP19), respectively. IC<sub>50</sub> values of <bold>5d</bold> were 5.09 and &gt;50 μ<sc>m</sc>, whereas these values for <bold>5g</bold> were &gt;50 μ<sc>m</sc> and 7.40 μ<sc>m</sc>, respectively, for CYP17A1 and CYP19. Molecular modelling highlighted that the inhibitor designed to bind cytochrome P450 haem iron is a necessary condition but not the only rationale to explain inhibitory activity. These abiraterone analogues were then evaluated on hormone‐independent prostate cancer cell lines DU‐145 and PC‐3 and on hormone‐dependent breast and prostate cancer cell lines MCF‐7 and LNCaP, respectively. Compounds <bold>5e</bold>, <bold> 5g</bold> and <bold>5i</bold> have showed potent activities only on hormone‐independent prostate cancer cell lines DU‐145 and PC‐3 with 60–85% inhibition of both cell viability and growth at 10 n<sc>m</sc> with pro‐apoptotic mechanism as illustrated in PC‐3 cells by DNA ladder assay and Western blotting of Bax, Casp‐3 and its substrate, the poly (ADP–ribose) polymerase. We conclude that hybrid heterocycle steroids could be good lead compounds in the drug design especially against hormone‐independent<abstract abstract-type="main" id="cbdd12195-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Nine new 17‐(piperazin‐1‐yl)pyridin‐5‐yl)steroids as abiraterone analogues were synthesized. Compounds <bold>5d</bold> and <bold>5g</bold> showed selective activities against 17α‐hydroxylase/C17, 20‐lyase (CYP17A1) and aromatase (CYP19), respectively. IC<sub>50</sub> values of <bold>5d</bold> were 5.09 and &gt;50 μ<sc>m</sc>, whereas these values for <bold>5g</bold> were &gt;50 μ<sc>m</sc> and 7.40 μ<sc>m</sc>, respectively, for CYP17A1 and CYP19. Molecular modelling highlighted that the inhibitor designed to bind cytochrome P450 haem iron is a necessary condition but not the only rationale to explain inhibitory activity. These abiraterone analogues were then evaluated on hormone‐independent prostate cancer cell lines DU‐145 and PC‐3 and on hormone‐dependent breast and prostate cancer cell lines MCF‐7 and LNCaP, respectively. Compounds <bold>5e</bold>, <bold> 5g</bold> and <bold>5i</bold> have showed potent activities only on hormone‐independent prostate cancer cell lines DU‐145 and PC‐3 with 60–85% inhibition of both cell viability and growth at 10 n<sc>m</sc> with pro‐apoptotic mechanism as illustrated in PC‐3 cells by DNA ladder assay and Western blotting of Bax, Casp‐3 and its substrate, the poly (ADP–ribose) polymerase. We conclude that hybrid heterocycle steroids could be good lead compounds in the drug design especially against hormone‐independent prostate cancer.</p> </abstract> … (more)
- Is Part Of:
- Chemical biology & drug design. Volume 82:Number 5(2013:Nov.)
- Journal:
- Chemical biology & drug design
- Issue:
- Volume 82:Number 5(2013:Nov.)
- Issue Display:
- Volume 82, Issue 5 (2013)
- Year:
- 2013
- Volume:
- 82
- Issue:
- 5
- Issue Sort Value:
- 2013-0082-0005-0000
- Page Start:
- 620
- Page End:
- 629
- Publication Date:
- 2013-10-16
- Subjects:
- Drugs -- Design -- Periodicals
Pharmaceutical chemistry -- Periodicals
Biochemistry -- Periodicals
615.19005 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&NEWS=n&PAGE=toc&D=ovft&AN=01253034-000000000-00000 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1747-0285 ↗
http://www.blackwell-synergy.com/loi/jpp ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cbdd.12195 ↗
- Languages:
- English
- ISSNs:
- 1747-0277
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3139.120000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3965.xml